<DOC>
	<DOCNO>NCT02916420</DOCNO>
	<brief_summary>This study aim assess efficacy safety pomalidomide combination low-dose dexamethasone Chinese patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Efficacy Safety Pomalidomide Combination With Low-dose Dexamethasone Chinese Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Have document diagnosis multiple myeloma Subjects must receive least 2 prior therapy . Subjects must undergo prior treatment least 2 cycle lenalidomide least 2 cycle bortezomib ( either separate regimen within regimen ) . Subjects must also document evidence progressive disease ( PD ) within 60 day ( measure end last cycle ) complete treatment last antimyeloma drug regimen use prior study entry . Subjects must measurable disease : serum Mprotein ≥ 5 g/L urine Mprotein ≥ 200 mg/24 hour involve free light chain ≥100 mg/L serum free light chain ratio ( κ/λ ratio &lt; 0.26 &gt; 1.65 ) abnormal Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤2 Life expectancy &gt; 3 month For female patient , naturally postmenopausal least 24 month , take surgical sterilization Women childbearing potential must : 1. 2 negative pregnancy test initiate pomalidomide . The first test perform within 1014 day , second test within 24 hour prior initiate pomalidomide 2. commit either abstain continuously heterosexual sexual intercourse use 2 method reliable birth control , begin 4 week prior initiate pomalidomide treatment , therapy , continue 4 week follow discontinuation pomalidomide therapy 3. agree perform pregnancy test study Male patient must always use condom sexual contact female reproductive potential take pomalidomide 4 week discontinue pomalidomide , even undergone successful vasectomy . Meanwhile male patient take pomalidomide must donate sperm . Subjects agree share medication another person Subjects able adhere study visit schedule protocol requirement Any serious medical condition , laboratory abnormality , psychiatric illness would prevent patient comply protocol put patient 's safety risk Evidence uncontrolled cardiovascular disease , congestive heart failure , unstable angina , myocardial infarction within 12 month prior enrollment Any follow laboratory abnormality : ANC &lt; 1×10^9/L PLT &lt; 75×10^9/L subject &lt; 50 % bone marrow nucleate cell plasma cell ; PLT &lt; 30×10^9/L subject ≥50 % bone marrow nucleate cell plasma cell Creatinine Clearance &lt; 45 mL/min AST ALT &gt; 3.0 x ULN Serum total bilirubin &gt; 34.2 μmol/L Corrected serum calcium &gt; 3.5 mmol/L Hemoglobin &lt; 80g/L Prior history malignancy , multiple myeloma , unless subject free disease ≥ 3 year . Exceptions include follow : Basal Squamous cell carcinoma skin Carcinoma situ cervix breast Incidental histologic find prostate cancer ( TNM stage T1a T1b ) Serious , uncontrolled medical condition active infection , include limited HIV antibody positive , HBsAg positive HBV DNA copy &gt; 1 × 10^3 , hepatitis C virus antibody positive , uncontrolled diabetes , patient require hemodialysis Hypersensitivity thalidomide , lenalidomide , dexamethasone Previous therapy pomalidomide Peripheral neuropathy ≥ Grade 2 Incidence gastrointestinal disease may significantly alter absorption pomalidomide Subjects receive follow within last 14 day initiation study treatment : plasmapheresis , major surgery , radiation therapy , use antimyeloma drug therapy Use investigational drug within 28 day prior enrollment Subjects condition require chronic steroid immunosuppressive treatment , rheumatoid arthritis , multiple sclerosis , lupus , etc . Patients unable unwilling undergo antithrombotic prophylactic treatment Subjects receive allogeneic hematopoietic stem cell transplant le 12 month prior enrollment Subjects plan eligible hematopoietic stem cell transplant Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>